We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Advanced Oncotherapy Plc | LSE:AVO | London | Ordinary Share | GB00BD6SX109 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.925 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -29.49M | -0.0549 | -0.35 | 10.32M |
TIDMAVO
RNS Number : 2542X
Advanced Oncotherapy PLC
09 August 2018
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Exercise of Warrants and Issue of Shares
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it yesterday issued 850,000 new ordinary shares ("New Shares") of 25 pence in the Company, pursuant to the exercise of 850,000 warrants at an average price of 26.5 pence per New Share.
Application has been made for the 850,000 New Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on or about 15 August 2018. The New Shares will rank pari passu in all aspects with the existing ordinary shares of the Company.
Total voting rights
Following Admission, the Company's enlarged issued share capital will comprise 156,479,233 ordinary shares, with voting rights. The Company does not hold any ordinary shares in treasury. Therefore the total number of ordinary shares in the Company with voting rights will be 156,479,233. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
Advanced Oncotherapy Plc www.avoplc.com Dr. Michael Sinclair, Executive Tel: +44 20 3617 8728 Chairman Nicolas Serandour, CEO Stockdale Securities (Nomad & Joint Broker) Antonio Bossi / Ed Thomas Tel: +44 20 7601 6100 Stifel Nicolaus Europe (Joint Broker) Jonathan Senior Tel: +44 20 7710 7600 Walbrook PR (Financial PR & IR) Tel: +44 20 7933 8780 or avo@walbrookpr.com Paul McManus / Anna Dunphy Mob: +44 7980 541 893 / Mob: +44 7876 741 001
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCPPMATMBAMBFP
(END) Dow Jones Newswires
August 09, 2018 02:00 ET (06:00 GMT)
1 Year Advanced Oncotherapy Chart |
1 Month Advanced Oncotherapy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions